



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/521,814

08/11/2006

Bipin C. M. Patel

1768-134

3777

6449

7590

12/26/2008

ROTHWELL, FIGG, ERNST & MANBECK, P.C.

1425 K STREET, N.W.

SUITE 800

WASHINGTON, DC 20005

EXAMINER

JONES, DAMERON LEVEST

ART UNIT

PAPER NUMBER

1618

NOTIFICATION DATE

DELIVERY MODE

12/26/2008

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-PAT-Email@rfem.com

Office Action Summary	Application No. 10/521,814	Applicant(s) PATEL, BIPIN C. M.	
	Examiner D. L. Jones	Art Unit 1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 1/22/06; 1/21/05; & 8/30/07.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 19-33 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 30 and 31 is/are allowed.
- 6) ☒ Claim(s) 19-29, 32 and 33 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>8/30/07</u> . | 6) <input type="checkbox"/> Other: _____ |

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 1/27/06 wherein claims 1-18 were canceled and claims 19-33 were added.

Note: Claims 19-33 are pending.

APPLICANT'S INVENTION

2. Applicant's invention is directed to conjugates comprising N-hydroxypropylmethacrylamide-methacrylate copolymers, a linker moiety, a chemotherapeutic agent, and a nuclide activation therapy agent as set forth in independent claims 19, 30, and 31.

112 FIRST PARAGRAPH REJECTIONS

Scope of Enablement Rejections

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 19-29, 32, and 33 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for NAT agents selected from the group consisting of o-carboranylalanine $B_{10}C_2H_2-CH_2CHCO_2NH_2$, carborane butamine $B_{10}C_2H_2-(CH_3)_3CHCO_2NH_2$, p-boronphenylalanine, $B_{12}H_{11}SH$, mercaptoundecahydrododecacarborate, boronated porphyrins, $B_{12}H_{11}SH$ glutathione disulfide, and water soluble tetracarbonylphenylporphyrin, does not reasonably provide enablement for all NAT (nuclide activation therapy agent). The specification does not

Art Unit: 1618

enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

There are several guidelines when determining if the specification of an application allows the skilled artisan to practice the invention without undue experimentation. The factors to be considered in determining what constitutes undue experimentation were affirmed by the court in *In re Wands* (8 USPQ2d 1400 (CAFC 1986)). These factors are (1) nature of the invention; (2) state of the prior art; (3) level of one of ordinary skill in the art; (4) level of predictability in the art; (5) amount of direction and guidance provided by the inventor; (6) existence of working examples; (7) breadth of claims; and (8) quantity of experimentation needed to make or use the invention based on the content of the disclosure.

(1) Nature of the invention

The claims are directed to conjugates comprising N-hydroxypropyl-methacrylamide methacrylate copolymer, linker, chemotherapeutic agent, and a nuclide activation therapy agent.

(2) State of the prior art

The references of record do not disclose the possible NAT agents that are compatible with the instant invention.

(3) Level of one of ordinary skill in the art

The level of one of ordinary skill in the art is high. Independent claim 19 encompasses a vast number of possible nuclide activation therapy agents. Applicant's

specification does not enable the public to make or use such a vast number of possible conjugates.

(4) Level of predictability in the art

The art pertaining to the therapy agents is highly unpredictable. Determining the various types of nuclide activation therapy agent requires various experimental procedures and without guidance that is applicable to all nuclide activation therapy agents, there would be little predictability in performing the claimed invention.

(5) Amount of direction and guidance provided by the inventor

Independent claim 19 encompasses a vast number of conjugates. Applicant's limited guidance as it relates to the NAT component does not enable the public to prepare such a numerous amount of copolymer conjugates. There is no directional guidance for the conjugates. Hence, there is no enablement for all possible permutations and combinations of the copolymer conjugates.

(6) Existence of working examples

Applicant's limited working examples do not enable the public to prepare such numerous amounts of NAT agents. While Applicant's claims encompass a plethora of possible NAT agents; however, the specification discloses o-carboranylalanine $B_{10}C_2H_2-CH_2CHCO_2NH_2$, carborane butamine $B_{10}C_2H_2-(CH_3)_3CHCO_2NH_2$, p-boronphenylalanine, $B_{12}H_{11}SH$, mercaptoundecahydrododecacarborate, boronated porphyrins, $B_{12}H_{11}SH$ glutathione disulfide, and water soluble tetracarbonylphenylporphyrin.

Art Unit: 1618

(7) Breadth of claims

The claims are extremely broad due to the vast number of possible NAT agents known to exist.

(8) Quantity of experimentation needed to make or use the invention based on the content of the disclosure

The specification does not enable any person skilled in the art to which it pertains to make or use the invention commensurate in scope with the claims. In particular, the specification fails to enable the skilled artisan to practice the invention without undue experimentation. Furthermore, based on the unpredictable nature of the invention, the state of the prior art, and the extreme breadth of the claims, one skilled in the art could not perform the claimed invention without undue experimentation.

Written Description Rejections

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 19-29, 32, and 33 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant is reminded that an Inventor is entitled to a patent to protect his work only if he/she produces or has possession of something truly new and novel. The

Art Unit: 1618

invention being claimed must be sufficiently concrete so that it can be described for the world to appreciate the specific nature of the work that sets it apart from what was before. The Inventor must be able to describe the item to be patented with such clarity that the Reader is assured that the Inventor actually has possession and knowledge of the unique composition that makes it worthy of patent protection. The instant application does not sufficiently describe the invention as it relates to the nuclide activation therapy agents specifically, the modified carborane cage, the boron containing nucleic acid precursor, the boron containing folate growth factor, the hormone, the radiation sensitizer, phosphates, phosphonate, phosphoramidates, barbiturate, and cyclic thiourea derivative . What the Reader gathers from the instant application is a desire/plan/first step for obtaining a desired result. While the Reader can certainly appreciate the desire for achieving a certain end result, establishing goals does not necessarily mean that an invention has been adequately described.

While compliance with the written description requirements must be determined on a case-by-case basis, the real issue here is simply whether an adequate description is necessary to practice an invention described only in terms of its function and/or based on a disclosure wherein a description of the components necessary in order for the invention to function are lacking. In order to satisfy the written description requirement, the specification must describe every element of the claimed invention in sufficient detail so that one of ordinary skill in the art would recognize that the Inventor possessed the claimed invention at the time of filing. In other words, the specification should describe an invention and does so in sufficient detail that one skilled in the art can clearly

Art Unit: 1618

conclude that the Inventor created what is the claimed. Thus, the written description requirement is lacking in the instant invention since the various terms as set forth above are not described in a manner to clearly allow persons of ordinary skill in the art to recognize that Applicant invented what is being claimed or how Applicant is interpreting the definitions.

112 SECOND PARAGRAPH REJECTIONS

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 19-29, 32, and 33 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 19-25, 27-29, 32, and 33: The claim as written is ambiguous because it is unclear what nuclide activation therapy agent Applicant is referring to that is compatible with the instant invention.

Claim 26: The claim as written is ambiguous because of the terms: modified carborane cage, boron containing nucleic acid precursor, hormone, radiation sensitizer, phosphates, phosphonates, phosphoramidates, and cyclic thiourea derivatives. In particular, the claims are ambiguous because it is unclear what modified, precursors, sensitizers, derivatives, etc. Applicant is claiming that are compatible with the instant invention. Please clarify in order that one may readily ascertain what is being claimed.

Claims 21: A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite,

Art Unit: 1618

since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 21 recites the broad recitation 'the polymer has a molecular weight of 5-100', and the claim also recites 'preferably 10-70...20-40kDa' which is the narrower statement of the range/limitation.

Claim 28: A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required

Art Unit: 1618

feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 28 recites the broad recitation 'a peptide', and the claim also recites 'preferably 1-10 amino acids in length' which is the narrower statement of the range/limitation.

Claim 29: A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 29 recites the broad recitation 'n represent an integer from 1-500, and the claim also recites 'preferably 1-100, particularly preferably 1-20' which is the narrower statement of the range/limitation.

Claim 24, lines 3-4: The claim is ambiguous because of the phrase 'in sufficient quantity to undergo a neutron capture reaction'. Specifically, it is unclear what one

Art Unit: 1618

considers 'sufficient' because what one individual considers as sufficient is not necessarily the same for another individual.

ALLOWABLE CLAIMS

9. Claims 30 and 31 are allowable over the prior art of record because the prior art neither anticipates nor renders obvious the two specific species set forth in the claims.

PRIORITY DOCUMENT

10. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

COMMENTS/NOTES

11. It should be noted that no prior art has been cited against the instant claims. However, Applicant MUST address and overcome the 112 rejections above.

12. In claim 26, line 3, Applicant is respectfully requested to correct the spelling of 'foliate' (did Applicant intend to write 'folate'). In claim 29, line 1, Applicant is respectfully requested to replace 'form' with 'from'.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/D. L. Jones/
Primary Examiner
Art Unit 1618

December 15, 2008